Neoadjuvant Chemotherapy for Breast Cancer: Evaluation by PET / CT

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Rania Ali Maarouf ◽  
Amgad S Abdel-Rahman ◽  
Samar Ibrahim Mohamed
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Therapeutic Response ◽  
Left Breast ◽  
Breast Lesions ◽  
Mean Values ◽  
Pet Ct ◽  
The Mean ◽  
Neo Adjuvant Chemotherapy ◽  
Fdg Pet Ct

Abstract Background Breast cancer (BC)is the most commonly occurring cancer in women and the second most common cancer overall.An increase in the rate of breast preservation has come to be expected because of tumor reduction using neo-adjuvant chemotherapy (NAC) for locally advanced cancer and it is important to accurately determine the effects of NAC. Patients and Methods This study was conducted on 30 female patients with histopathologically confirmed breast cancer referred for a PET/CT scan aiming to demonstrate the role of 18F-FDG PET/CT in detecting the pathological response to NAC in BC patients. Results No statistically significant differences were found between the baseline number of lesions and that after three cycles of chemotherapy. Also, no statistically significant differences were found between the mean values of baseline and after three cycles of chemotherapy of both liver activity and size of right breast lesions. Meanwhile, the mean values of SUV of right and left breast lesions as well as the size of left breast lesions were significantly lower after three cycles of chemotherapy when compared to their baseline values. And no statistically significant differences were found between complete and partial therapeutic response in the right breast lesions as well as between complete and no therapeutic response in the left breast lesions as regards baseline SUV and SUV after 3 cycles of chemotherapy. Conclusion It can be concluded that FDG-PET/CT is useful for evaluation of neo-adjuvant chemotherapy for breast cancer. However, more studies are needed to validate the results of the current study.

scholarly journals Quantitative Evaluation of Therapeutic Response by FDG-PET–CT in Metastatic Breast Cancer

2016 ◽  
Vol 3 ◽  
Author(s):  
Dorothée Goulon ◽  
Hatem Necib ◽  
Brice Henaff ◽  
Caroline Rousseau ◽  
Thomas Carlier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Quantitative Evaluation ◽  
Fdg Pet ◽  
Therapeutic Response ◽  
Metastatic Breast ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals The diagnostic significance of breast incidentalomas detected on whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography

2015 ◽  
Vol 01 (02) ◽  
pp. 092-096
Author(s):  
Shelly Sharma ◽  
Ankur Pruthi
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Emission Tomography ◽  
Whole Body ◽  
Diagnostic Significance ◽  
Focal Uptake ◽  
Positron Emission ◽  
Pet Ct ◽  
The Mean ◽  
Fdg Pet Ct

ABSTRACT Objective: The objective of this study was to establish the diagnostic significance of breast incidentalomas detected on whole-body fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Materials and Methods: We retrospectively analyzed the data of 3868 patients who underwent 18F FDG PET/CT at our institution, for the presence of hypermetabolic focus in the breasts. Patients with known breast cancer or with the previous history of breast cancer were excluded from the study. Ten out of remaining 3868 patients had abnormal focal uptake in the breast. We, therefore, enrolled these 10 patients with histopathology confirmation in this study. Results: Among all 3868 patients, 10 (0.25%) patients demonstrated incidental focal uptake in breast parenchyma. All of these 10 patients were females. Histopathology examination confirmed malignancy in 8 out of 10 patients (80%), these included invasive ductal cancer in 4 patients, non-Hodgkin's lymphoma in 2 patients, and metastasis from rectal cancer and endometrial cancer, respectively, in 2 patients. Of the 10 patients, 2 (20%) had lesions that were confirmed to be benign. Both of these were proven to be fibroadenomas. The mean maximum standardized uptake value (SUVmax) on FDG-PET/CT scans was 1.35 ± 1.2 in the benign cases versus 3.8 ± 1.83 in the malignant cases. This difference was statistically insignificant (P = 0.056). All malignant lesions had SUVmax 2.0 or greater. The mean size differed significantly between the benign and malignant groups (2.55 ± 0.63 vs. 1.31 ± 0.44 cm) (P = 0.005) with benign lesions being bigger in size. Conclusion: Unexpected focal areas of hypermetabolic activity discovered in the breast at the time of PET/CT are associated with a high likelihood of malignancy in as many as 80% of cases. Therefore, any suspicious activity discovered in the breast on PET/CT should be evaluated until a diagnosis is found.

scholarly journals Elastographic Evaluation of Indeterminate Breast Masses on Ultrasound

2016 ◽  
Vol 39 (02) ◽  
pp. 072-079 ◽  
Author(s):  
Luciana Graziano ◽  
Almir Bitencourt ◽  
Marcela Cohen ◽  
Camila Guatelli ◽  
Miriam Poli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Qualitative Analysis ◽  
Subcutaneous Tissue ◽  
Statistical Significance ◽  
Breast Lesions ◽  
Surgical Biopsy ◽  
Mean Values ◽  
Conventional Ultrasound ◽  
The Mean

Objective To evaluate the diagnostic accuracy of elastography for breast cancer identification in patients with indeterminate lesions on ultrasound. Methods This prospective, descriptive study included patients with indeterminate breast lesions in the ultrasound and with indication for percutaneous or surgical biopsy. The elastography was evaluated by qualitative analysis and by two methods for the semi quantitative analysis. Results We evaluated 125 female patients with 159 lesions, with a mean age of 47 years, and a range of 20–85 years. Ultrasound has shown to be a method with good sensitivity (98.1%), but with a lower specificity (40.6%). On the elastography qualitative analysis, the specificity and accuracy were of 80.2% and 81.8% respectively. The mean size of the lesions showed no difference in classification by elastography. For the semiquantitative elastography, the mean values ​​of the malignant lesions were statistically higher when compared with the subcutaneous tissue or the adjacent fibroglandular tissue. The analysis of the receiver operating characteristic (ROC) curves for these two semiquantitative methods showed that both are considered satisfactory, with an area under the curve above 0.75 and statistical significance (p < 0.0001). The best results were obtained when using the findings of combined conventional ultrasound and qualitative elastography, with 100% sensitivity and 63.2% specificity. Conclusions Elastography can be a useful complementary method, increasing the specificity and diagnostic accuracy of conventional ultrasound for the diagnosis of breast cancer in patients with indeterminate breast lesions.

scholarly journals Carcinoma en Cuirasse from Recurrent Breast Cancer seen on FDG-PET/CT

2015 ◽  
Vol 5 ◽  
pp. 35 ◽  
Author(s):  
Aung Zaw Win ◽  
Carina Mari Aparici
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Ductal Carcinoma ◽  
Recurrent Breast Cancer ◽  
Left Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Pet Ct ◽  
Recurrent Breast ◽  
Fdg Pet Ct

Our patient was a 36-year-old female diagnosed with Grade II ER+/PR−/Her-2 − ductal carcinoma in situ (DCIS) in the left breast. She underwent left lumpectomy and received treatment with tamoxifen and radiotherapy. Three years later, she presented with multiple diffused skin nodules on the chest and upper left arm. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) exam showed widespread metastasis in the chest, upper left arm, left axillary lymph nodes, and left suprascapular muscle. FDG-PET/CT imaging of breast carcinoma en cuirasse is very rare. FDG-PET/CT is useful in detecting recurrent breast cancer.

Role of PET/CT in Breast Cancer

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 35-35
Author(s):  
Z.A. Ali ◽  
M.S. Abdullah ◽  
M.M. Houseni ◽  
D.H. Hashem
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Distant Metastasis ◽  
Breast Lesions ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Enhanced Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Introduction: Breast cancer is the most common cancer type in women and the leading cause of cancer-related deaths in women worldwide. F-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) is widely used in the initial staging, evaluation of the therapeutic response, and detection of recurrent disease. However, with the increasing use of FDG PET/CT, sites of increased activity have been occasionally discovered in unexpected locations which may not correlate with the patient’s clinical history or the expected spread of the primary malignancy. The aim of this study is to detect the diagnostic value of PET/CT in breast cancer patients; comparing PET/CT performance with that of contrast enhanced CT in diagnosis of breast cancer and distant metastasis. Material and Methods: A prospective study carried out at National liver institute –Menoufia University from January 2016 to December 2017. It included 30 female patients. All patients had pathologically confirmed breast cancer. All patients underwent 18F-FDG PET/CT examination. Patients fasting for about 6 hours before study, then 370–550 MBq of 18F-FDG was injected. Approximately after 60 min from injection, PET/CT scans were performed. Following PET imaging, volumetric contrast enhanced CT scanning was performed from skull base to mid-thigh on the same PET/CT machine. Images were reconstructed and viewed on workstation. Results: The study included 30 female patients with breast cancer, mean age: 53.56 years ±10.64 (SD), age range: 33-73years. Detection of contralateral breast affection in 2 patients (6.7%) and distant metastasis were seen on PET/CT. Sites of distant metastasis included: bone (n=12), axillary lymph nodes (n=11), cervical lymph nodes (n=6), mediastinal lymph nodes (n=12), abdominal lymph nodes (n=8), liver (n=5), lung (n=11) and other visceral sites metastasis (n=9).PET/CT detected breast lesions with a sensitivity of 100% and specificity of 95.4%. In contrast, the sensitivity and specificity of CT alone were 81.2% and 90.4% respectively. Conclusion: PET/CT has superiority over CT alone in detecting breast lesions and distant metastases.

Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population

2016 ◽  
Vol 9 (2) ◽  
pp. 169-177 ◽  
Author(s):  
Laura Evangelista ◽  
Francesco Bertagna ◽  
Mattia Bertoli ◽  
Tigu Stela ◽  
Giorgio Saladini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Male Breast ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Diagnostic And Prognostic Value

scholarly journals Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients

2021 ◽  
Author(s):  
Shozo Ohsumi ◽  
Sachiko Kiyoto ◽  
Mina Takahashi ◽  
Seiki Takashima ◽  
Kenjiro Aogi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Prospective Study ◽  
Cancer Patients ◽  
Scalp Cooling ◽  
Breast Cancer Patients ◽  
Chemotherapy Infusion ◽  
Group A ◽  
Neo Adjuvant Chemotherapy ◽  
Group B

Abstract Purpose Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We conducted a prospective study of hair recovery after chemotherapy with scalp cooling. Patients and methods One hundred and seventeen Japanese female breast cancer patients who completed planned (neo)adjuvant chemotherapy using the Paxman Scalp Cooling System for alopecia prevention were evaluated for alopecia prevention in our prospective study. We evaluated their hair recovery 1, 4, 7, 10, and 13 months after chemotherapy. Primary outcomes were grades of alopecia judged by two investigators (objective grades) and patients’ answers to the questionnaire regarding the use of a wig or hat (subjective grades). Results Of 117 patients, 75 completed scalp cooling during the planned chemotherapy cycles (Group A), but 42 discontinued it mostly after the first cycle (Group B). Objective and subjective grades were significantly better in Group A than in Group B throughout 1 year, and at 4 and 7 months after chemotherapy. When we restricted patients to those with objective Grade 3 (hair loss of > 50%) at 1 month, Group A exhibited slightly faster hair recovery based on the objective grades than Group B. There was less persistent alopecia in Group A than in Group B. Conclusions Scalp cooling during chemotherapy infusion for Japanese breast cancer patients increased the rate of hair recovery and had preventive effects against persistent alopecia.

Sign in / Sign up

Export Citation Format

Share Document